ANGO - AngioDynamics, Inc.
| Previous Close | 23.42 |
| Open | 23.49 |
| Bid | 21.81 x 2900 |
| Ask | 28.00 x 1300 |
| Day's Range | 23.03 - 23.54 |
| 52 Week Range | 15.16 - 24.24 |
| Volume | 396,363 |
| Avg. Volume | 253,027 |
| Market Cap | 871.64M |
| Beta | 0.71 |
| PE Ratio (TTM) | 53.43 |
| EPS (TTM) | 0.44 |
| Earnings Date | Sep 27, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.50 |
- Zacks•3 days ago
AngioDynamics (ANGO) Q1 Earnings Preview: What to Watch Ahead of the Release
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•4 days ago
What's in Store for AngioDynamics (ANGO) in Q1 Earnings?
Expanding product portfolio, international market expansion and cost-saving initiatives to drive AngioDynamics (ANGO) in Q1.
- Business Wire•4 days ago
AngioDynamics to Present at the Cantor Global Healthcare Conference
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C.
- Zacks•5 days ago
Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now
AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.
- Zacks•9 days ago
AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
- American City Business Journals•10 days ago
AngioDynamics expands oncology business with acquisition of Houston co.
The transaction comes as AngioDynamics consolidates and expands its oncology business at its Glens Falls, New York, manufacturing complex.
- Business Wire•10 days ago
AngioDynamics to Report Fiscal 2019 First Quarter Financial Results on September 27, 2018
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2019 before the market open on Thursday, September 27, 2018.
- Business Wire•11 days ago
AngioDynamics to Acquire RadiaDyne and its Revolutionary OARtrac® Radiation Dose Monitoring Platform to Further Expand Oncology Portfolio
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.
- Zacks•17 days ago
New Strong Sell Stocks for September 7th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Simply Wall St.•21 days ago
How Should You Think About AngioDynamics Inc’s (NASDAQ:ANGO) Risks?
If you own shares in AngioDynamics Inc (NASDAQ:ANGO) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...
- Business Wire•last month
AngioDynamics to Present at Two Investor Conferences in September
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announc
- Zacks•last month
New Strong Sell Stocks for August 23rd
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- GlobeNewswire•last month
Factors of Influence in 2018, Key Indicators and Opportunity within Okta, Great Lakes Dredge & Dock, MDC Partners, Colfax, Heritage-Crystal Clean, and AngioDynamics — New Research Emphasizes Economic Growth
NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Okta, ...
- Zacks•last month
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.
- Business Wire•last month
AngioDynamics Provides Updates on Oncology and Vascular Access Businesses
AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today provided a corporate update on enhancements made to its Oncology business and acknowledged a recent, favorable U.S. District Court ruling that impacts its Vascular Access business. As part of its strategic focus on building a continuum of care within the oncology space, AngioDynamics has announced the acquisition of the BioSentry Tract Sealant System (BioSentry) technology from Surgical Specialties, LLC, a medical device company headquartered in Westwood, Massachusetts.
- Zacks•last month
Why Is AngioDynamics (ANGO) Up 5.02% Since Its Last Earnings Report?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•2 months ago
Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day
Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day
- Associated Press•2 months ago
Medical device company settles US case over false claims
A New York-based medical device company will pay the U.S. government $12.5 million to resolve allegations that it had health care providers submit false claims to federal programs. The Department of Justice ...
- Reuters•2 months ago
AngioDynamics to pay $12.5 mln over false claims allegations -U.S. Justice Dept
AngioDynamics Inc has agreed to pay the U.S. government $12.5 million to resolve allegations it caused healthcare providers to submit false claims to federal healthcare programs over the use of two medical devices, the Justice Department said on Wednesday. The New York-based medical device maker will pay $11.5 million over allegations it was the distributor for Biocompatibles Plc of the LC Bead for use as a drug-delivery device in combination with chemotherapy drugs from May 2006 through December 2011, the department said in a statement.
- ACCESSWIRE•2 months ago
Free Post Earnings Research Report: AngioDynamics' Revenues Improved 1.6%; Adjusted EPS Advanced 5.3%
LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want access to our free earnings report on AngioDynamics, Inc. (NASDAQ: ANGO), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ANGO. The Company reported its financial results on July 11, 2018, for the fourth quarter and full fiscal year 2018. In addition, the Company provided its guidance for the full fiscal year 2019.
- Zacks•2 months ago
AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife
AngioDynamics' (ANGO) fourth-quarter performance dull; stiff competition a serious concern.
- Zacks•2 months ago
AngioDynamics (ANGO) Misses Q4 Earnings & Revenue Estimates
AngioDynamics (ANGO) misses Q4 earnings and revenue estimates; international sales high.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ANGO earnings conference call or presentation 11-Jul-18 12:00pm GMT
Q4 2018 AngioDynamics Inc Earnings Call
- Associated Press•2 months ago
AngioDynamics: Fiscal 4Q Earnings Snapshot
The Latham, New York-based company said it had profit of 6 cents per share. Earnings, adjusted for one-time gains and costs, were 20 cents per share. The medical device maker posted revenue of $88.3 million ...
